The ability of ertumaxomab to induce cytotoxicity against tumor cell lines with low HER2 antigen density, may provide a novel therapeutic option for breast cancer patients when trastuzumab treatment is inappropriate [39]. The gene discussed is ERBB2; the disease is breast carcinoma.